Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 05/22/2019

2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the ASCO Annual Meeting External Link in Chicago, IL from June 1 – June 3, 2019 in oral and poster sessions.

Oral Sessions

Time Title Location
Saturday, June 1
2:21 PM – 2:33 PM Novel Combinations with Distinct Mechanisms of Action External Link
Discussant: Geraldine O’Sullivan Coyne, MD, PhD, Developmental Therapeutics Clinic
Hall D1
Sunday, June 2
8:00 AM – 11:00 AM Developmental Immunotherapy and Tumor Immunobiology Oral Poster Session External Link
Co-Chair: Naoko Takebe, MD, PhD, Developmental Therapeutics Clinic
Hall D2
8:00 AM – 8:12 AM Phase I Study of Pembrolizumab in People with HIV and Cancer External Link Hall D2
8:24 AM – 8:36 AM Identification of Targetable Molecular Alterations in the NCI-COG Pediatric MATCH Trial External Link S504
Monday, June 3
8:24 AM – 8:36 AM Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E/K Mutations: Results from the Molecular Analysis for Therapy Choice (MATCH) Arm H External Link S406

Poster Presentations

Time Title Poster/Abstract
Saturday, June 1
8:00 am – 11:00 am Design and Development of the Molecular Analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network External Link Poster: 8
Abstract: 3016
8:00 am – 11:00 am Development and Analytical Validation of a 523-gene Clinical Assay for Cell-free DNA External Link Poster: 31
Abstract: 3039
8:00 am – 11:00 am Safety and Tolerability of Veliparib, an Oral PARP Inhibitor, and M6620 (VX-970), an ATR Inhibitor, in combination with Cisplatin in Patients with Refractory Solid Tumors External Link Poster: 59
Abstract: 3067
8:00 am – 11:00 am Integrative Analyses of Signaling and DNA Damage Repair Pathways in Patient-derived Xenograft (PDX) Models from NCI’s Patient-Derived Models Repository (PDMR) External Link Poster: 103
Abstract: 3111
8:00 am – 11:00 am Measuring Phospho-MET by Multiplex Immunofluorescence to Aid in Selection of Patients with MET Activation in Tumors External Link Poster: 123
Abstract: 3131
8:00 am – 11:00 am Pharmacodynamics of PI3K, MEK, and AKT Inhibitors through Isoform-specific Measurements of MEK, ERK, AKT, and ribosomal protein S6 in Needle Biopsies External Link Poster 126:
Abstract 3134
8:00 am – 11:00 am Phase I Trial of 5-aza-4’-thio-deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors External Link Poster: 139a
Abstract: TPS3148
8:00 am – 11:00 am Organ Disfunction (dys) and Clinical Outcomes in Patients (pts) Treated with Immune Checkpoint Inhibitors (ICIs) External Link Poster: 213
Abstract: 2569
8:00 am – 11:00 am TMB Standardization by Alignment to Reference Standards: Phase II of the Friends of Cancer Research TMB Harmonization Project External Link Poster: 268
Abstract: 2624
8:00 am – 11:00 am A Multiplex Immunofluorescence Assay to Assess Immune Checkpoint Inhibitor-targeted CD8 Activation and Tumor Colocalization in FFPE Tissues External Link Poster: 273
Abstract: 2629
8:00 am – 11:00 am SWOG 1609 (DART): A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors External Link Poster: 295a
Abstract: TPS2658
8:00 am – 11:00 am Evaluation of the Multi-kinase Inhibitor Regorafenib in the Pediatric Preclinical Testing Consortium Osteosarcoma, Rhabdomyosarcoma, and Ewing Sarcoma In Vivo Models External Link Poster: 420
Abstract: 10038
1:15 pm – 4:15 pm A Randomized Double-blind Placebo-controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with Adavosertib in Women with Recurrent, Platinum Resistant Epithelial Ovarian Cancer: A Trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia External Link Poster: 341
Abstract: 5518
Sunday, June 2
8:00 am – 11:00 am A Phase Ib Trial of CB-839 (Telaglenastat) in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma (NCT03528642) External Link Poster: 262a
Abstract: TP2075
Monday, June 3
8:00 am – 11:00 am The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089/NCT03038672) External Link Poster: 322a
Abstract: TPS7570
1:15 pm – 4:15 pm Treatment Completion and Toxicity of Trastuzumab or Trastuzumab + Lapatinib in Older Patients (pts): BIG 2-06; NCCTG N063D (Alliance) External Link Poster: 245
Abstract 11553
1:15 pm – 4:15 pm A Randomized Phase II Study of Atezolizumab Plus Recombinant Human IL-7 (CYT107) or Atezolizumab Alone in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14) External Link Poster: 412a
Abstract: TPS4586